Alembic Pharmaceuticals has restructured its internal reporting structure effective June 2, 2026, resulting in the cessation of Mr. Atul Suri and Mr. Prag Goel as Senior Management Personnel. The company stated that these executives will now report to Mr. Ramesh Juneja, the newly appointed Executive Vice President – Human Health (Sales and Marketing), India Business. This organizational change was disclosed to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Mr. Juneja, who assumed his role on June 1, 2026, brings over three decades of experience in pharmaceutical sales and marketing. A pharmacy graduate from Sant Gadge Baba Amravati University and an MBA holder from Symbiosis International University, he has previously held leadership positions at Sun Pharmaceutical Industries and Cipla. Prior to joining Alembic Pharmaceuticals , he founded the Ramesh Juneja Business Advisory and co-founded BJW Health Pvt. Ltd.

The changes in the senior management hierarchy are detailed in the table below:

Alembic Pharmaceuticals will participate in the 16th Annual Global Investor Conference, titled Trinity India 2026, hosted by B&K Securities in Mumbai on May 29, 2026. The company plans to engage with institutional investors through physical meetings held on a one-to-one basis and in group settings to discuss its performance and outlook. The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company confirmed that no unpublished price sensitive information (UPSI) will be shared during these meetings. This assurance ensures compliance with regulatory standards regarding the dissemination of material non-public information.

The notification was addressed to BSE Limited and the National Stock Exchange of India Ltd to keep the information on record. G. Krishnan, the Chief Financial Officer of the company, signed the communication.